MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’)
announced today that it had successfully closed a financing round of five million Euros to
fund the continued expansion and growth of the company.
The financing round was led by BayBG, a key equity investor for Proteros. The financing
round is the third and largest investment into the firm since the inception of Proteros.
Two new financial institutions were part of a consortium alongside of BayBG. The
proceeds will be used to support the development of the company, with a particular focus
on investment into Proteros’ further downstream drug discovery capabilities. Moreover,
the financing will strengthen the Company’s equity capital base and reduce its current
overall financing and debt servicing costs.
In tandem with the financing, Proteros announced it will re-align the Company’s
organization and expand the integrated drug discovery services business. Prominent in
these measures will be the deployment of further medicinal chemistry staff that will
assist in growing the Company’s drug discovery capabilities, which are being expanded in
response to market demand. Proteros’ world-class core analytical services capabilities,
including X-Ray crystallography, kinetic/thermodynamic profiling and custom protein
supply, will continue to form the basis for future development.
Dr. Torsten Neuefeind, Chief Executive Officer and founder of Proteros, stated:”We are
happy to have closed our third, and to-date, largest-ever financing round. Additionally we
are also very pleased to welcome two new financing partners in this financing round, as
well as to receive the strong continued support of BayBG. With the Company’s strong
partnerships associated with its analytics business, Proteros is ideally positioned to make
the next step into drug discovery applications.”
Proteros is a privately held Life Sciences company based in Munich, Germany that
provides services and proprietary technologies to support drug discovery programs of the
largest pharmaceutical companies. The company accelerates and improves protein
structure analysis and structure-based drug discovery with its expertise and unique
technologies for crystallography and fragment-based lead generation. Proteros
complements its clients’ capabilities. Proteros currently provides services for more than
eighty pharmaceutical and biotechnology clients in North America, Europe and Asia.
Proteros biostructures GmbH
Dr. Torsten Neuefeind
Phone: +49 (0) 89 700 761-0